EUVIMEDEUVIMED entdecken
Crossref

Genomics of Long‐Term Complications of Childhood Leukemia: Rationale and Design of the GenLEA Study

Mathilde Veneziano-Broccia iD, Gerard Michel, Jean-Hugues Dalle, Jean-François Deleuze, Robert Olaso, Gaëlle Munsch, Marine Germain, Caroline Meguerditchian, Stéphane Ducassou iD, Carine Domenech, Marie-Dominique Tabone iD, Pascal Auquier und 3 weitere

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Mathilde Veneziano-Broccia und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, Immunology and Oncology, La Timone Children's Hospital, APHM, INSERM, INRAe, C2VN, Aix Marseille Université, Mars…. Hauptthemen laut MEDLINE: Genomics, Osteonecrosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Metabolic Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: French National Clinical Research Program, French National Cancer Institute, French National Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Survivors of childhood acute leukemia are at risk of long‐term treatment‐related complications, but the role of genetic susceptibility remains unclear. We describe here the GenLEA project, which was established to investigate genetic determinants of long‐term complications.

Methods

GenLEA builds on the French LEA cohort, which prospectively follows acute leukemia survivors since 2004 through standardized dedicated consultations every 2 to 4 years. Patients were selected from the nested CryoLEA biobank. Cases were defined as survivors with at least one of four major complications (anthracycline‐related cardiomyopathy, secondary malignant neoplasms, metabolic syndrome, or osteonecrosis) while controls were survivors without these complications, selected with the objective of a 1:3 case‐to‐control ratio. Genetic data were generated using genome‐wide genotyping and whole‐exome sequencing.

Results

After quality control, 743 patients were included for analyses (241 cases and 502 controls). Fifty‐one percent were male with a median age at diagnosis of 7.3 years (IQR 3.9–13.0), and median follow‐up reached 14 years (IQR 7.9–19.8). Among the cases, 44 had cardiomyopathy, 50 osteonecrosis, 37 secondary malignant neoplasms, and 163 metabolic syndrome. Planned analyses include genome‐wide association studies (GWAS) and downstream analyses such as transcriptome‐wide association studies (TWAS) and Mendelian randomization on genotyping data, as well as gene‐based tests on exome sequencing data. Perspectives By integrating these approaches with high‐quality clinical information, GenLEA offers a unique opportunity to identify molecular determinants of late complications after childhood acute leukemia. This collaborative resource will support replication efforts, meta‐analyses, and ultimately the development of personalized long‐term follow‐up strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GenomicsOsteonecrosisPrecursor Cell Lymphoblastic Leukemia-LymphomaMetabolic SyndromeCardiomyopathiesNeoplasms, Second PrimaryHumansChildMaleFemaleChild, PreschoolAdolescentFollow-Up StudiesProspective StudiesCase-Control StudiesAnthracyclinesGenetic Predisposition to DiseasePrognosisCancer Survivors

Stichwörter der Autor:innen

acute leukemiagenomicslong‐term complications

Substanzen

Anthracyclines

Autor:innen und Institutionen

  • Department of Pediatric Hematology, Immunology and Oncology, La Timone Children's Hospital, APHM, INSERM, INRAe, C2VN, Aix Marseille Université, Marseille, France.
  • Bordeaux Population Health Research Center, Bordeaux, France.
  • Department of Pediatric Hematology, Immunology and Oncology, La Timone Children's Hospital, APHM, CERESS, Aix Marseille Université, Marseille, France.
  • Department of Hematology and Immunology, Hôpital Robert-Debré, GHU APHP-Nord Université Paris-Cité, Paris, France.
  • CRYOSTEM, Marseille, France.
  • CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, Evry, France.

ORCID-Profile: Mathilde Veneziano-Broccia, Stéphane Ducassou, Marie-Dominique Tabone

Förderung

  • French National Clinical Research Program
  • French National Cancer Institute
  • French National Research Agency
  • Association Laurette Fugain
  • Association Action Leucémies
  • Association Tribal Sport
  • Agence Nationale de la Recherche
  • Canceropôle PACA

Zitieren

APA

Veneziano-Broccia, M., Michel, G., Dalle, J. H., Deleuze, J. F., Olaso, R., Munsch, G., Germain, M., Meguerditchian, C., Ducassou, S., Domenech, C., Tabone, M. D., Auquier, P., Berbis, J., Tregouet, D. A., & Saultier, P. (2026). Genomics of Long‐Term Complications of Childhood Leukemia: Rationale and Design of the GenLEA Study. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70027

Vancouver

Veneziano-Broccia M, Michel G, Dalle JH, Deleuze JF, Olaso R, Munsch G, et al. Genomics of Long‐Term Complications of Childhood Leukemia: Rationale and Design of the GenLEA Study. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70027

BibTeX
@article{VenezianoBroccia2026,
  author = {Veneziano-Broccia, Mathilde and Michel, Gerard and Dalle, Jean-Hugues and Deleuze, Jean-François and Olaso, Robert and Munsch, Gaëlle and Germain, Marine and Meguerditchian, Caroline and Ducassou, Stéphane and Domenech, Carine and Tabone, Marie-Dominique and Auquier, Pascal and Berbis, Julie and Tregouet, David-Alexandre and Saultier, Paul},
  title = {Genomics of Long‐Term Complications of Childhood Leukemia: Rationale and Design of the GenLEA Study},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70027}
}
Kostenlos starten →